Prevalence of Serious Bleeding Events and Intracranial Hemorrhage in Patients Receiving Activated Protein C: A Systematic Review and Meta-analysis

Khan, Ajmal; Agarwal, Ritesh; Aggarwal, Ashutosh N.; Gupta, Dheeraj
July 2010
Respiratory Care;Jul2010, Vol. 55 Issue 7, p901
Academic Journal
BACKGROUND: Activated protein C reduces 28-day mortality in patients with severe sepsis, but its anticoagulant properties entail a risk of bleeding. OBJECTIVE: The aim of this systematic review was to evaluate the prevalence of serious bleeding events in patients receiving activated protein C. METHODS: We searched the MEDLINE and EMBASE databases for studies that described the prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C. We calculated the bleeding rates by calculating proportions and 95% CIs for each study, and then pooled the data to derive a pooled proportion and 95% CI. RESULTS: Our search yielded 17 studies, which included 10,679 patients. The occurrence of serious bleeding events in patients receiving activated protein C ranged from 0.5% to 9.6%, and the pooled prevalence was 3.3% (95% CI 2.4-4.4%) by the random effects model. The occurrence of intracranial hemorrhage ranged from 0% to 1.4%, and the pooled prevalence was 0.44% (95% CI 0.31- 0.6%). Sensitivity analysis showed a higher prevalence of bleeding in the observational studies than in the randomized controlled trials. There was substantial clinical and statistical heterogeneity, but no evidence of publication bias. CONCLUSIONS: Activated protein C is associated with significant risk of bleeding, so strict inclusion and exclusion criteria should be set prior to administering activated protein C.


Related Articles

  • An Engineered Factor Va Prevents Bleeding Induced by Anticoagulant wt Activated Protein C. von Drygalski, Annette; Bhat, Vikas; Gale, Andrew J.; Burnier, Laurent; Cramer, Thomas J.; Griffin, John H.; Mosnier, Laurent O. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Objective: An increased risk of bleeding is observed in patients receiving activated protein C (APC), which may be a limiting factor for the application of novel APC therapies. Since APC's therapeutic effects often require its cytoprotective activities on cells but not APC's anticoagulant...

  • Risks and Benefits of Activated Protein C Treatment for Severe Sepsis. Warren, H. Shaw; Suffredini, Anthony F.; Eichacker, Peter Q.; Munford, Robert S. // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p1027 

    Discusses the risks and benefits of activated protein C treatment for severe sepsis. The two phases of the activated protein C trial; Subgroups and restrictions to use in high-risk patients; The risk of serious hemorrhage; The conclusion that activated C is effective with some patients.

  • Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients. Taha, Salma; D'Ascenzo, Fabrizio; Moretti, Claudio; Omedè, Pierluigi; Montefusco, Antonio; Bach, Richard G.; Alexander, Karen P.; Mehran, Roxana; Ariza-Solé, Albert; Zoccai, Giuseppe Biondi; Gaita, Fiorenzo // Advances in Interventional Cardiology;2015, Vol. 11 Issue 3, p182 

    Introduction: Due to its negative impact on prognosis, a clear assessment of bleeding risk for patients presenting with acute coronary syndrome (ACS) remains crucial. Different risk scores have been proposed and compared, although with inconsistent results. Aim: We performed a meta-analysis to...

  • Advances in Sepsis Therapy. Glück, Thomas; Opal, Steven M. // Drugs;2004, Vol. 64 Issue 8, p837 

    During the past 3 years new insights have been gained into the fundamental elements that underlie the pathogenesis of sepsis, and after years of frustrating failures, progress in the basic understanding of sepsis has translated into successful new therapies. These new treatment strategies have...

  • Refined bleeding estimates in adults starting anticoagulants. Steinberg, Benjamin A. // BMJ: British Medical Journal;8/9/2014, Vol. 349 Issue 7970, p5 

    The author reflects on the assessment of the risk of bleeding in patients with atrial fibrillation who take anticoagulants in Great Britain. He focuses on the outpatient derivation cohorts which involved 9000 intracranial haemorrhages and 20,000 major upper gastrointestinal bleeding using the...

  • Dabigatran etexilate.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p104 

    The article presents a case study of a 71-year-old woman suffering from life-threatening hemorrhage after administration of oral anticoagulant dabigatran etexilate.

  • Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. Skaistis, Joel; Tagami, Travis // PLoS ONE;9/18/2015, Vol. 10 Issue 9, p1 

    Background: The reversibility of new/novel oral anticoagulants (NOAC) is not well understood, whereas the reversal strategies for bleeding associated with vitamin k antagonists (VKA), such as warfarin, is well established. It is unknown whether outcomes are different between bleeds occurring...

  • Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis. Lu, Dasheng; Zhang, Qi; Liu, Qian; Wang, Kai; Wang, Shengchan; Shan, Qijun // Journal of Interventional Cardiac Electrophysiology;Nov2015, Vol. 44 Issue 2, p105 

    Background: Comprehensive comparisons of safety (measured by bleeding risk) between multiple novel oral anticoagulants (NOACs and warfarin) in the peri-procedural period of catheter ablation (CA) for atrial fibrillation (AF) are rare.Methods and Results: MEDLINE,...

  • Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials. Li, Shuang; Liu, Baoxin; Xu, Dachun; Xu, Yawei // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Objective(s): Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored. Methods: Medline, Embase and Web of Science were searched to March 8, 2014 for prospective, randomized controlled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics